Tests a procedure that blocks adrenal arteries for hard-to-control high blood pressure
Tests a procedure blocking adrenal gland arteries in adults with hard-to-control high blood pressure.
Plain-language title generated from the registry record
Registry title: Superselective Adrenal Arterial Embolization for Refractory Hypertension: A Proof-of-Concept Study
Key facts
- Where
- Nanchang, ChinaSee the site
Where in China
- The Second Affiliated Hospital of Nanchang UniversityNanchang, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Second Affiliated Hospital of Nanchang University
- Trial code
- NCT06568640
- Record updated
- 23 August 2024
- Original description
The subjects of this study were patients with essential refractory hypertension. The purpose of this study is to evaluate the safety and efficacy of superselective adrenal arterial embolization (SAAE) in patients with primary refractory hypertension and to explore the possibility of SAAE in patients with primary refractory hypertension.After the subject completes the SAAE, an 8-week follow-up will be conducted to assess the safety and effectiveness of the SAAE.Read full original descriptionShow less
Evaluation and Exploration of the Safety and Efficacy of Superselective Adrenal Arterial Embolization in Patients With Essential Refractory Hypertension: A Proof-of-Concept Study
The subjects of this study were patients with essential refractory hypertension. The purpose of this study is to evaluate the safety and efficacy of superselective adrenal arterial embolization (SAAE) in patients with primary refractory hypertension and to explore the possibility of SAAE in patients with primary refractory hypertension.After the subject completes the SAAE, an 8-week follow-up will be conducted to assess the safety and effectiveness of the SAAE.
Inclusion: Age > 18 years, no gender restrictions; Primary refractory hypertension: Taking three antihypertensive drugs, including a - diuretic, with an average office systolic blood pressure ≥150 mmHg measured three times; Duration of hypertension greater than 6 months; Standing plasma aldosterone and renin activity not below the lower limit of the unit's reference range; Signed informed consent form.
Exclusion: Type 1 diabetes, uncontrolled hyperthyroidism, malignant arrhythmias, malignant tumors, decompensated heart failure, severe liver dysfunction, severe hematological diseases, severe obstructive sleep apnea syndrome, history of myocardial infarction, syncope, cerebral hemorrhage, or cerebral infarction within the past 3 months; Presence of other severe organic diseases that would make the patient unable to tolerate superselective adrenal arterial embolization; Severe allergy to contrast agents; Morning cortisol level < 4.3 µg/dL; estimated glomerular filtration rate (eGFR) < 45 mL/min/1.73 m²; serum potassium level > 5.5 mmol/L; Pregnant women or those planning to conceive within the next year; Adrenal mass with a diameter exceeding 2 cm; Patients enrolled or planning to participate in other clinical studies that could impact the results of this study.